TMC
RGLS

Trellus Management Company’s Regulus Therapeutics RGLS Stock Holding History

Trellus Management Company’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-431
Closed -$451K – 81
2015
Q4 		$451K Sell
431
-402
-48% -$403K 0.66% 50
2015
Q3 		$654K Buy
833
+166
+25% +$170K 0.96% 30
2015
Q2 		$877K Buy
667
+378
+131% +$610K 0.99% 26
2015
Q1 		$588K Buy
+289
New +$628K 0.7% 43

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Trellus Management Company's RGLS Position: Q1 2016 in Review

Trellus Management Company sold out of Regulus Therapeutics (RGLS) in Q1 2016, closing a stake of 431 shares — an estimated $451K sold.

Trellus Management Company first reported a position in RGLS in Q1 2015 and held it in 4 quarters. The position peaked at $877K in Q2 2015. 101 funds tracked by Wall St. Rank hold RGLS as of Q1 2016.

  • Trellus Management Company reported no remaining Regulus Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Trellus Management Company sold 431 Regulus Therapeutics shares in Q1 2016, an estimated $451K.
  • Trellus Management Company first reported a position in Regulus Therapeutics in Q1 2015 and held it in 4 quarters.
  • Trellus Management Company's Regulus Therapeutics position peaked at $877K in Q2 2015.
  • 101 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2016.

Based on Trellus Management Company's 13F filing for Q1 2016, filed 4 May 2016.